Page last updated: 2024-11-13
rebaudioside m
Description
rebaudioside M: a sweetening agent isolated from Stevia rebaudiana; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
rebaudioside M : A rebaudioside that is rebaudioside A in which the the hydroxy groups at positions 2 and 3 of the beta-D-glucosyl ester moiety have both been converted to the corresponding beta-D-glucoside. Found in very low concentraitions in the leaves of Stevia Rebaudiana, it is more than 200 times sweeter than sucrose. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|
| Stevia | genus | A plant genus of the family ASTERACEAE. Members contain stevioside and other sweet diterpene glycosides. The leaf is used for sweetening (SWEETENING AGENTS).[MeSH] | Asteraceae | A large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH] |
| Stevia rebaudiana | species | [no description available] | Asteraceae | A large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH] |
Cross-References
Synonyms (29)
| Synonym |
|---|
| reb-x |
| reb m |
| reb x |
| CHEBI:145019 , |
| rebaudioside x |
| rebaudioside m |
| reb-m |
| beta-d-glucopyranosyl-(1->2)-[beta-d-glucopyranosyl-(1->3)]-1-o-(13alpha-{[beta-d-glucopyranosyl-(1->2)-[beta-d-glucopyranosyl-(1->3)]-beta-d-glucopyranosyl]oxy}-18-oxo-5beta,8alpha,9beta,10alpha-kaur-16-en-18-yl)-beta-d-glucopyranose |
| 1220616-44-3 |
| S3282 |
| AC-34451 |
| GSGVXNMGMKBGQU-PHESRWQRSA-N |
| fqa8xmc4xj , |
| fema no. 4922 |
| unii-fqa8xmc4xj |
| fema no. 4895 |
| kaur-16-en-18-oic acid, 13-((o-beta-d-glucopyranosyl-(1->2)-o-(beta-d-glucopyranosyl-(1->3))-beta-d-glucopyranosyl)oxy)-, o-beta-d-glucopyranosyl-(1->2)-o-(beta-d-glucopyranosyl-(1->3))-beta-d-glucopyranosyl ester, (4alpha)- |
| Q63393666 |
| DTXSID701019863 , |
| rebaudiosidem |
| HY-N6833 |
| CS-0100251 |
| MS-32094 |
| kaur-16-en-18-oic acid, 13-((o-.beta.-d-glucopyranosyl-(1->2)-o-(.beta.-d-glucopyranosyl-(1->3))-.beta.-d-glucopyranosyl)oxy)-, o-.beta.-d-glucopyranosyl-(1->2)-o-(.beta.-d-glucopyranosyl-(1->3))-.beta.-d-glucopyranosyl ester, (4.alpha.)- |
| dtxcid201477733 |
| beta-d-glucopyranosyl-(1->2)-(beta-d-glucopyranosyl-(1->3))-1-o-(13alpha-((beta-d-glucopyranosyl-(1->2)-(beta-d-glucopyranosyl-(1->3))-beta-d-glucopyranosyl)oxy)-18-oxo-5beta,8alpha,9beta,10alpha-kaur-16-en-18-yl)-beta-d-glucopyranose |
| E80657 |
| AKOS040758812 |
| CHEMBL5095195 |
Roles (1)
| Role | Description |
|---|
| sweetening agent | Substance that sweeten food, beverages, medications, etc. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (3)
| Class | Description |
|---|
| beta-D-glucoside | Any D-glucoside in which the anomeric centre has beta-configuration. |
| tetracyclic diterpenoid | A diterpenoid with a tetracyclic skeleton. |
| rebaudioside | Any of the steviol glycosides found in the leaves of the stevia plant, Stevia rebaudiana. They are typically more than 100 times sweeter than sucrose. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 54.66
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 54.66 (24.57) | | Research Supply Index | 1.95 (2.92) | | Research Growth Index | 4.80 (4.65) | | Search Engine Demand Index | 94.36 (26.88) | | Search Engine Supply Index | 2.35 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |